443 results on '"Przepiorka, D."'
Search Results
2. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
3. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis
4. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey
5. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus
6. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
7. Tacrolimus clearance is age-dependent within the pediatric population
8. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation
9. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide
10. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
11. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study
12. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation
13. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia
14. The use of topical cyclosporin A in ocular graft-versus-host-disease
15. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2
16. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation
17. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir
18. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect
19. Allogeneic blood stem cell transplantation in advanced hematologic cancers
20. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma
21. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis
22. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity
23. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients
24. Characteristics of human dendritic cells generated in a microgravity analog culture system
25. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients
26. Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion
27. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections
28. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer
29. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
30. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
31. Long-term outcome of a Phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients
32. Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system
33. The Midlatitude Trough and the Plasmapause in the Nighttime Ionosphere Simultaneously Observed by DEMETER During 2006–2009.
34. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study
35. Clinical Observations, Interventions, and Therapeutic Trials. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia
36. Phase I trial of cyclosporine (CSA) induced autologous graft versus host disease (GVHD) in patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT)
37. A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma
38. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity
39. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity
40. ETOPOSIDE, CYCLOPHOSPHAMIDE, TOTAL-BODY IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION-AN EFFECTIVE TREATMENT FOR HEMATOLOGIC MALIGNANCIES
41. HO-166 DOTMP, A BONE SEEKING RADIOCHELATE FOR SELECTIVE MARROW RADIOTHERAPY WITH BONE-MARROW TRANSPLANTATION (BMT) FOR MULTIPLE-MYELOMA
42. PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE (TBC) WITH AUTOLOGOUS BMT FOR HIGH-RISK LYMPHOMA
43. The effect of changes in the treatment paradigm for chronic lymphocytic leukemia: A tumor registry study
44. African Americans with hepatocellular carcinoma have worse survival than Caucasians: A tumor registry study
45. Long-term survival in Hodgkin’s disease: A tumor registry study
46. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
47. The CDC Guidelines for Prevention of Infections: rule with reason
48. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506 [2]
49. FDA–NCI Workshop on Tumor Vaccines
50. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.